TSLP and asthma: Currently, there are several anti-TSLP monoclonal antibodies under development (Matera et al., 2020; O’Byrne et al., 2023), in which tezepelumab demonstrated positive results in treating patients with poorly controlled severe asthma in the phase 3 clinical trial (Menzies-Gow et al., 2021).